William T. Symonds

Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: An integrated safety and efficacy analysis

Hepatology 2015cited by 256position: middledoi

Virological response after 6 week triple-drug regimens for hepatitis C: a proof-of-concept phase 2A cohort study

The Lancet 2015cited by 151position: middledoi

Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection

New England Journal of Medicine 2014cited by 1,702position: middledoi

Ledipasvir and Sofosbuvir for Previously Treated HCV Genotype 1 Infection

New England Journal of Medicine 2014cited by 1,304position: middledoi

Daclatasvir plus Sofosbuvir for Previously Treated or Untreated Chronic HCV Infection

New England Journal of Medicine 2014cited by 1,191position: middledoi

Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis

New England Journal of Medicine 2014cited by 1,122position: middledoi

Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study

The Lancet 2014cited by 815position: middledoi

Sofosbuvir and Ribavirin in HCV Genotypes 2 and 3

New England Journal of Medicine 2014cited by 797position: middledoi

Sofosbuvir and Ribavirin for Treatment of Compensated Recurrent Hepatitis C Virus Infection After Liver Transplantation

Gastroenterology 2014cited by 341position: middledoi

Sofosbuvir and Ribavirin Prevent Recurrence of HCV Infection After Liver Transplantation: An Open-Label Study

Gastroenterology 2014cited by 330position: middledoi

Sofosbuvir and Ribavirin for Hepatitis C in Patients With HIV Coinfection

JAMA 2014cited by 254position: middledoi

Infrequent Development of Resistance in Genotype 1–6 Hepatitis C Virus–Infected Subjects Treated With Sofosbuvir in Phase 2 and 3 Clinical Trials

Clinical Infectious Diseases 2014cited by 213position: middledoi

Concordance of sustained virological response 4, 12, and 24 weeks post‐treatment with sofosbuvir‐containing regimens for hepatitis C virus

Hepatology 2014cited by 196position: middledoi

Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection

New England Journal of Medicine 2013cited by 1,780position: middledoi

Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options

New England Journal of Medicine 2013cited by 1,081position: middledoi

Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial

The Lancet Infectious Diseases 2013cited by 328position: middledoi

Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial

The Lancet 2013cited by 296position: middledoi

Sofosbuvir and Ribavirin for Hepatitis C Genotype 1 in Patients With Unfavorable Treatment Characteristics

JAMA 2013cited by 286position: middledoi

Recent publications

Grants

Frequent collaborators